Live Breaking News & Updates on Castle Biosciences Daily

Stay updated with breaking news from Castle biosciences daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Castle Biosciences (NASDAQ:CSTL) Stock Price Up 8.8%

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) shares rose 8.8% during trading on Wednesday . The stock traded as high as $23.51 and last traded at $23.44. Approximately 139,605 shares were traded during trading, a decline of 42% from the average daily volume of 241,645 shares. The stock had previously closed at $21.55. Analyst […] ....

Derekj Maetzold , Castle Biosciences , Robertw Baird , Riverpark Advisors , China Universal Asset Management Co , Castle Biosciences Inc , Wuxi Apptec Co , Allspring Global Investments Holdings , Securities Exchange Commission , Assetmark Inc , Get Free Report , Exchange Commission , Park Advisors , Universal Asset Management , Global Investments Holdings , Wuxi Apptec , Mypath Melanoma , Castle Biosciences Daily ,

Castle Biosciences (NASDAQ:CSTL) Shares Down 4.7%

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report)’s share price fell 4.7% during mid-day trading on Tuesday . The stock traded as low as $21.90 and last traded at $22.12. 111,875 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 240,997 shares. The stock had previously closed at […] ....

Derekj Maetzold , Castle Biosciences , Robertw Baird , Daniel Bradbury , Allspring Global Investments Holdings , China Universal Asset Management Co , Riverpark Advisors , Assetmark Inc , Wuxi Apptec Co , Castle Biosciences Inc , Get Free Report , Biosciences Stock Down , Director Daniel Bradbury , Park Advisors , Universal Asset Management , Global Investments Holdings , Wuxi Apptec , Mypath Melanoma , Castle Biosciences Daily ,

Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,368 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Derek J. Maetzold sold 2,368 shares of Castle Biosciences stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $23.40, for a total transaction of $55,411.20. Following the transaction, the insider now directly owns 57,893 shares of the company’s […] ....

Robertw Baird , Derekj Maetzold , Castle Biosciences , Bellevue Group , Castle Biosciences Inc , Deerfield Management Companylp Series , Vanguard Group Inc , Jacobs Levy Equity Management Inc , Principal Financial Group Inc , Securities Exchange Commission , Get Free Report , Exchange Commission , Financial Group , Jacobs Levy Equity Management , Levy Equity Management , Mypath Melanoma , Castle Biosciences Daily ,